Translational Oncology
Global cancer occurrence has increased from 12.7 million new cases in 2008 to 14.1 million in 2012, and it is expected that the incidence will rise by around 70% over the next two decades. A comprehensive understanding of the pathophysiological processes underlying cancer development is of utmost importance for the development of detection techniques, diagnostic and prognostic markers, new therapies, risk assessment tools, and cancer prevention strategies.
Characterizing the molecular basis of cancer is a rapidly progressing area of research, with many laboratory discoveries translating into important advances that impact patient care. Our new cross-journal article collection on Translational Oncology aims to showcase the results of novel research findings that bridge the gap between basic science and cancer medicine.
The journals included in this collection are BMC Medicine, BMC Cancer, Cancers of the Head and Neck, Clinical Sarcoma Research and Journal of Experimental and Clinical Cancer Research. We are seeking submissions of research articles that provide important developments in cancer research. Preclinical studies should provide a significant advance in knowledge, and have clear potential for strong clinical impact. This collection will also include invited reviews, debates and commentaries. If you have any original research you would like us to consider for inclusion our Translational Oncology collection, please submit directly to your journal of choice, and state within your cover letter that you want the submission to be considered for this Translational Oncology article collection.
Guest Edited by Prof Tommaso Dragani (Fondazione IRCCS Istituto Nazionale dei Tumori, Italy), the series is now accepting submissions of research articles that provide important developments in cancer research.
Please choose from the following list of journals to submit your article to:
- REVIEW
Molecular chess? Hallmarks of anti-cancer drug resistance
The development of resistance is a problem shared by both classical chemotherapy and targeted therapy. Patients may respond well at first, but relapse is inevitable for many cancer patients, despite many impro...BMC Cancer 2017 17:10Published on: 5 January 2017 - COMMENTARY
Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors – assessment of intra-tumour heterogeneity
Intra-tumour heterogeneity is a common molecular phenomenon in metastatic clear cell renal carcinoma (mRCC), representing the genetic complexity of a tumour with multiple metastatic sites. The present commenta...BMC Medicine 2016 14:201Published on: 7 December 2016 - RESEARCH
Exosomes play an important role in the process of psoralen reverse multidrug resistance of breast cancer
Release of exosomes have been shown to play critical roles in drug resistance by delivering cargo. Targeting the transfer of exosomes from resistant cells to sensitive cells may be an approach to overcome some...Journal of Experimental & Clinical Cancer Research 2016 35:186Published on: 1 December 2016 - COMMENTARY
Genomic profiling for copy number changes in plasma of ovarian cancer patients – a new era for cancer diagnostics?
A blood test that can detect human malignancy with high clinical sensitivity and specificity is highly desirable. To achieve this, a tumor marker is needed that correlates with tumor burden and that can be mea...BMC Medicine 2016 14:186Published on: 17 November 2016 - RESEARCH ARTICLE
Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma
Molecular intratumour heterogeneity (ITH) is common in clear cell renal carcinomas (ccRCCs). However, it remains unknown whether this is mirrored by heterogeneity of drug responses between metastases in the sa...BMC Medicine 2016 14:185Published on: 14 November 2016 - REVIEW
Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer
The rapidly expanding arsenal of chemotherapeutic agents approved in the past 5 years represents significant progress in the field. However, this poses a challenge for oncologists to choose which drug or combi...BMC Cancer 2016 16:850Published on: 5 November 2016 - RESEARCH ARTICLE
Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone
The spatial relationship of glioblastoma (GBM) to the subventricular zone (SVZ) is associated with inferior patient survival. However, the underlying molecular phenotype is largely unknown. We interrogated an ...BMC Medicine 2016 14:170Published on: 26 October 2016 - RESEARCH ARTICLE
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set
While clinical outcomes following immunotherapy have shown an association with tumor mutation load using whole exome sequencing (WES), its clinical applicability is currently limited by cost and bioinformatics...BMC Medicine 2016 14:168Published on: 25 October 2016 - RESEARCH ARTICLE
Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells
High-grade non-muscle invasive bladder cancer (NMIBC) has a high risk of recurrence and progression to muscle-invasive forms, which seems to be largely related to the presence of tumorigenic stem-like cell pop...BMC Medicine 2016 14:163Published on: 21 October 2016 - RESEARCH ARTICLE
Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma
The prognostic significance of tumor-associated macrophages (TAM) in adult classical Hodgkin lymphoma (cHL) remains controversial. Here, we report a meta-analysis of the association of CD68 and CD163 infiltrat...BMC Medicine 2016 14:159Published on: 17 October 2016 - RESEARCH ARTICLE
Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening
Non-invasive prenatal testing (NIPT) identifies fetal aneuploidy by sequencing cell-free DNA in the maternal plasma. Pre-symptomatic maternal malignancies have been incidentally detected during NIPT based on a...BMC Medicine 2016 14:126Published on: 24 August 2016 - FORUM
Major milestones in translational oncology
Translational oncology represents a bridge between basic research and clinical practice in cancer medicine. Today, translational research in oncology benefits from an abundance of knowledge resulting from geno...BMC Medicine 2016 14:110Published on: 28 July 2016
.png)
No hay comentarios:
Publicar un comentario